Dexamphetamine—a restricted stimulant drug used to treat narcolepsy and Attention Deficient Hyperactivity Disorder ...

Although there is no cure for narcolepsy, medication and lifestyle changes can help manage the symptoms. Medicines that ...

The FDA approves AXSM's Symbravo for the acute treatment of migraine with or without aura in adults. The latest nod diversifies its commercial portfolio.

and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in ...

The FDA approves AVDL's Lumryz for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven years and older with narcolepsy. -- LUMRYZ is the only FDA-approved once ...

People who live with narcolepsy — about one out of every 2,000 Americans — don’t have many options when it comes to treatment. The milder form of narcolepsy includes symptoms of excessive ...

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...

Two international studies have revealed hundreds of previously unknown genetic links to depression, which could allow ...

Spasmodic dysphonia impacts about 50,000 people in North America. Here's what to know about what causes spasmodic dysphonia ...

As with climate change, why are we so slow to recognise the existential threat that drug use poses to humanity?

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...

Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm of Japan's ...